Literature DB >> 35226299

New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.

Yalin Liu1,2, Xianghang Luo3,4.   

Abstract

Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism. GLP-1 can also delay stomach emptying and suppress appetite to help lose weight. This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.
© 2022. Higher Education Press.

Entities:  

Keywords:  obesity; semaglutide; type 2 diabetes

Mesh：

Substances：

Year:  2022        PMID： 35226299      PMCID： PMC8883012          DOI： 10.1007/s11684-021-0873-2

Source DB:  PubMed          Journal:  Front Med        ISSN： 2095-0217            Impact factor:   9.927


  63 in total

1.  The FDA's assessment of two drugs for chronic weight management.

Authors:  Eric Colman; Julie Golden; Mary Roberts; Amy Egan; Joyce Weaver; Curtis Rosebraugh
Journal:  N Engl J Med       Date:  2012-10-10       Impact factor: 91.245

Review 2.  Weight management in type 2 diabetes: current and emerging approaches to treatment.

Authors:  Luc Van Gaal; André Scheen
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

3.  Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.

Authors:  Ofri Mosenzon; Thalia Marie Blicher; Signe Rosenlund; Jan W Eriksson; Simon Heller; Ole Holm Hels; Richard Pratley; Thozhukat Sathyapalan; Cyrus Desouza
Journal:  Lancet Diabetes Endocrinol       Date:  2019-06-09       Impact factor: 32.069

4.  Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome.

Authors:  Michael J Wilkinson; Emily N C Manoogian; Adena Zadourian; Hannah Lo; Savannah Fakhouri; Azarin Shoghi; Xinran Wang; Jason G Fleischer; Saket Navlakha; Satchidananda Panda; Pam R Taub
Journal:  Cell Metab       Date:  2019-12-05       Impact factor: 27.287

5.  Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression.

Authors:  A De Vos; H Heimberg; E Quartier; P Huypens; L Bouwens; D Pipeleers; F Schuit
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

6.  Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice.

Authors:  Youngmi Song; Jacqueline A Koehler; Laurie L Baggio; Alvin C Powers; Darleen A Sandoval; Daniel J Drucker
Journal:  Cell Metab       Date:  2019-09-05       Impact factor: 27.287

7.  Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.

Authors:  Luc Van Gaal; Xavier Pi-Sunyer; Jean-Pierre Després; Christine McCarthy; André Scheen
Journal:  Diabetes Care       Date:  2008-02       Impact factor: 19.112

8.  Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.

Authors:  Helena W Rodbard; Ildiko Lingvay; John Reed; Raymond de la Rosa; Ludger Rose; Danny Sugimoto; Eiichi Araki; Pei-Ling Chu; Nelun Wijayasinghe; Paul Norwood
Journal:  J Clin Endocrinol Metab       Date:  2018-06-01       Impact factor: 5.958

Review 9.  Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning.

Authors:  Daniel J Drucker
Journal:  Cell Metab       Date:  2021-01-21       Impact factor: 27.287

Review 10.  Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care.

Authors:  Marco Orsini Federici; Raffaella Gentilella; Antonella Corcos; Enrico Torre; Stefano Genovese
Journal:  Diabetes Metab Res Rev       Date:  2021-02-07       Impact factor: 4.876
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.